Company intelligence / Profile preview
Advanced Tissue Sciences
- Ownership
- Private
- Development stage
- Preclinical
Overview
Advanced Tissue Sciences was a pioneer in tissue engineering, commercializing Dermagraft for diabetic foot ulcers and a separate product for burn treatment. Despite FDA approval and scientific achievement, the company struggled with reimbursement and market adoption. It filed for bankruptcy in 2002; its assets were acquired by Smith & Nephew. The company also had early-stage programs in cardiac repair and cartilage regeneration[1][3][5].
- Therapeutic areas
- EndocrinologyCardiovascularDermatologyInfectious Diseases
- Modalities
- Cell therapyBiologicScaffold-based tissue engineering products
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Advanced Tissue Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Advanced Tissue Sciences.